Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases

Monitoring anti-TNF agents in inflammatory bowel disease (IBD) patients may be helpful in optimizing outcomes. We aimed to evaluate potential correlations among demographic, clinical, laboratory, or imaging parameters, as well as serum levels of infliximab (IFX) and adalimumab (ADA) and their respec...

Descripción completa

Detalles Bibliográficos
Autores principales: Grinman, Ana B., de Souza, Maria das Graças C., Bouskela, Eliete, Carvalho, Ana Teresa P., de Souza, Heitor S. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478556/
https://www.ncbi.nlm.nih.gov/pubmed/32150077
http://dx.doi.org/10.1097/MD.0000000000019359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478556/
https://www.ncbi.nlm.nih.gov/pubmed/32150077
http://dx.doi.org/10.1097/MD.0000000000019359

Ejemplares similares